Pharm
Golimumab
search
Golimumab
, Simponi
See Also
Tumor Necrosis Factor Inhibitor
Monoclonal Antibody
Certolizumab
Etanercept
Adalimumab
Infliximab
Indications
Ulcerative Colitis
Psoriatic Arthritis
Rheumatoid Arthritis
Ankylosing Spondylitis
Contraindications
See
Tumor Necrosis Factor Inhibitor
Not approved for use in children
Dosing
See
Monoclonal Antibody
for preparation for use
Background
Injection sites include thigh,
Abdomen
and outer upper arm (rotate injection sites)
Available as a
Preload
ed syringe or autoinjector
Refrigerate and protect from light
Allow to warm to room
Temperature
for 15 to 30 minutes before injection (decreased pain)
Ulcerative Colitis
Start: 200 mg SQ week 0
Next: 100 mg SQ week 2
Next: 100 mg SQ every 4 weeks
Rheumatoid Arthritis
,
Psoriatic Arthritis
, Akylosing Spondylitis
SQ
Maintenance: 50 mg SQ every month
IV
Induction: Infuse 2 mg/kg IV over 30 minutes at week 0 and 4 weeks
Maintenance: Infuse 2 mg/kg IV over 30 minutes every 8 weeks
Mechanism
See
Tumor Necrosis Factor Inhibitor
Monoclonal Antibody
against human
Tumor Necrosis Factor
alpha
Precautions
See
TNF Inhibitor
TNF Inhibitor
s predispose to serious infections and malignancy
Prepare for
TNF Inhibitor
use with infection screening (e.g.
Tuberculosis
) and
Immunization
s
See
Monoclonal Antibody
Adverse Effects
See
Tumor Necrosis Factor Inhibitor
Safety
Considered safe in
Lactation
Unknown safety in pregnancy (registry exists)
Resources
Golimumab Injection Solution (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
(2023) Drugs for
Inflammatory Bowel Disease
, Med Lett Drug Ther 65: 105-12
Type your search phrase here